335 related articles for article (PubMed ID: 21278454)
1. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
Aly A; Ganesan S
J Mol Cell Biol; 2011 Feb; 3(1):66-74. PubMed ID: 21278454
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
4. REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Xu G; Chapman JR; Brandsma I; Yuan J; Mistrik M; Bouwman P; Bartkova J; Gogola E; Warmerdam D; Barazas M; Jaspers JE; Watanabe K; Pieterse M; Kersbergen A; Sol W; Celie PHN; Schouten PC; van den Broek B; Salman A; Nieuwland M; de Rink I; de Ronde J; Jalink K; Boulton SJ; Chen J; van Gent DC; Bartek J; Jonkers J; Borst P; Rottenberg S
Nature; 2015 May; 521(7553):541-544. PubMed ID: 25799992
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
[TBL] [Abstract][Full Text] [Related]
6. The p53-binding protein 1-Tudor-interacting repair regulator complex participates in the DNA damage response.
Zhang A; Peng B; Huang P; Chen J; Gong Z
J Biol Chem; 2017 Apr; 292(16):6461-6467. PubMed ID: 28213517
[TBL] [Abstract][Full Text] [Related]
7. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
[TBL] [Abstract][Full Text] [Related]
9. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
Weaver AN; Cooper TS; Rodriguez M; Trummell HQ; Bonner JA; Rosenthal EL; Yang ES
Oncotarget; 2015 Sep; 6(29):26995-7007. PubMed ID: 26336991
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
Barazas M; Gasparini A; Huang Y; Küçükosmanoğlu A; Annunziato S; Bouwman P; Sol W; Kersbergen A; Proost N; de Korte-Grimmerink R; van de Ven M; Jonkers J; Borst GR; Rottenberg S
Cancer Res; 2019 Feb; 79(3):452-460. PubMed ID: 30530501
[TBL] [Abstract][Full Text] [Related]
11. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
[TBL] [Abstract][Full Text] [Related]
12. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
Helleday T
Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475
[TBL] [Abstract][Full Text] [Related]
13. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
Ashworth A
J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
[TBL] [Abstract][Full Text] [Related]
14. CtIP-mediated resection is essential for viability and can operate independently of BRCA1.
Polato F; Callen E; Wong N; Faryabi R; Bunting S; Chen HT; Kozak M; Kruhlak MJ; Reczek CR; Lee WH; Ludwig T; Baer R; Feigenbaum L; Jackson S; Nussenzweig A
J Exp Med; 2014 Jun; 211(6):1027-36. PubMed ID: 24842372
[TBL] [Abstract][Full Text] [Related]
15. 53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice.
Chen J; Li P; Song L; Bai L; Huen MSY; Liu Y; Lu LY
Cell Death Differ; 2020 Sep; 27(9):2552-2567. PubMed ID: 32139898
[TBL] [Abstract][Full Text] [Related]
16. PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1.
Belotserkovskaya R; Raga Gil E; Lawrence N; Butler R; Clifford G; Wilson MD; Jackson SP
Nat Commun; 2020 Feb; 11(1):819. PubMed ID: 32041954
[TBL] [Abstract][Full Text] [Related]
17. 53BP1-shieldin-dependent DSB processing in BRCA1-deficient cells requires CST-Polα-primase fill-in synthesis.
Mirman Z; Sasi NK; King A; Chapman JR; de Lange T
Nat Cell Biol; 2022 Jan; 24(1):51-61. PubMed ID: 35027730
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
[TBL] [Abstract][Full Text] [Related]
19. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
[TBL] [Abstract][Full Text] [Related]
20. RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1.
Nakada S; Yonamine RM; Matsuo K
Cancer Res; 2012 Oct; 72(19):4974-83. PubMed ID: 22865450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]